Yazar "Ozcan, ME" seçeneğine göre listele
Listeleniyor 1 - 5 / 5
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Antioxidant enzyme activities and oxidative stress in affective disorders(Lippincott Williams & Wilkins, 2004) Ozcan, ME; Gulec, M; Ozerol, E; Polat, R; Akyol, ORecent data from several reports indicate that free radicals are involved in the biochemical mechanisms underlying neuropsychiatric disorders in human. The results of several reports suggest that lower antioxidant defences against lipid peroxidation exist in patients with depression and that there is a therapeutic benefit from antioxidant supplementation in unstable manic-depressive patients. We investigated the antioxidant enzyme status and the indices of oxidative stress and lipid peroxidation end products in erythrocytes from patients with affective disorder. For this purpose, we measured superoxide dismutase (SOD), glutathione peroxidase (GSH-Px) and catalase (CAT) activities, as well as malondialdehyde (MDA) and nitric oxide (NO) levels in patients with affective disorders (n=30) in both pre- and post-treatment periods, and in a control group (n = 21). CAT activities were significantly decreased in both pre-, and post-treatment periods in patients compared to the control group. GSH-Px activity in the pre-treatment period in the patients was significantly lower than both post-treatment patient and control groups. MDA levels were increased in both pre-, and post-treatment patient groups compared to the control group. NO level was lower in the pre-treatment patient group than in the control group. There were statistically significant correlations between SOD and MDA, and SOD and NO in the pre-treatment patient and control groups. Because the overall study sample was small, and the post-treatment patient group was even smaller, it can tentatively be suggested that the antioxidant system is impaired during a mood episode in patients with affective disorders, normalizing at the end of the episode. (C) 2004 Lippincott Williams Wilkins.Öğe Efficacy of lithium,valproate and carbarnazepine after an acute episode(Blackwell Publishing, 2004) Ozcan, ME; Polat, R; Genc, M; Unal, S[Abstract Not Available]Öğe Gonadal hormones in schizophrenia and mood disorders(Springer Heidelberg, 2003) Ozcan, ME; Banoglu, RThere are gender-related differences in the prevalence, course and treatment response characteristics of schizophrenia and mood disorders. Gonadal steroids exert potent effects on mood, cognition and behavior, and there is little doubt that androgens are crucial for differentiating to each gender. Serum level of total testosterone, free testosterone, estradiol and sex hormone binding globulin was measured in 69 medication-free men with either schizophrenia (n = 29) or bipolar I disorder, manic episode (n = 18) or major depressive disorder (n = 22). There was a statistically significant difference in free testosterone level between mania and schizophrenia groups (p < 0.05). The higher free testosterone level in the mania group compared to the schizophrenia group found in this study supports further investigation of a potential difference in the hypothalamic-pituitary-gonadal axis between patients with schizophrenia and bipolar I disorder, manic.Öğe Methodological considerations for the development of new treatments for bipolar disorder(Blackwell Science Asia, 1999) Potter, WZ; Ozcan, MELithium has been the drug of choice in treating bipolar disorder for 50 years and, therefore, patterns of response associated with its use define what we expect from treatment. Although efforts to establish some other agents as antimanic have been successful, it is difficult to assess their overall efficacy in relation to that of lithium without a better understanding of inclusion/exclusion criteria, subtypes, definitions of remission, relapse and recurrence, and duration of study. All of these factors need to be carefully addressed to identify the most important clinical targets for new drug development. Additional relevant information emerges from studies on combinations of mood stabilisers, efficacy of antimanic agents in different patient populations, analysis of rates of drop-out, non-compliance, suicide, drug abuse, and discontinuation especially with long-term treatment. Agents other than lithium that are effective in the acute phase treatment are still not well characterised as mood stabilisers. New agents need to be evaluated in the context of long-term treatment and the targeting of specific components of the syndrome beyond mania.Öğe Weight gain and improvement with quetiapine in bipolar I disorder - A case report(Pergamon-Elsevier Science Ltd, 2004) Ozcan, ME; Kaya, B; Polat, RObservations made with quetiapine (QUET) in this case give clues for some aspects of its use for patients with bipolar disorder. Weight gain (11 kg; 16.6% increase in 21 weeks) and improvement in manic symptoms occurred after QUET add-on to lithium (Li). Patient's mood improved after QUET add-on without causing extrapyramidal symptoms (EPS), while QUET was discontinued due to weight gain. Shortterm QUET add-on to Li may help mood stabilization in bipolar I disorder. Weight changes must be observed carefully. (C) 2003 Elsevier Inc. All rights reserved.
